Acetyl-L-Carnitine Prevents Methamphetamine-Induced Structural Damage on Endothelial Cells via ILK-Related MMP-9

S Fernandes1,2,3, S Salta1,2, J Bravo1,4

  • 1Addiction Biology Group, IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, Rua do Campo Alegre, 823, 4150-180, Porto, Portugal.

Molecular Neurobiology
|December 4, 2014
PubMed

Insights

Methamphetamine damages the blood-brain barrier by activating MMP-9 and ILK. Acetyl-L-carnitine (ALC) protects against this damage by inhibiting MMP-9, preserving tight junctions and actin structure.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cell Biology

Background:

  • Methamphetamine (METH) use compromises blood-brain barrier (BBB) integrity.
  • Matrix metalloproteinases (MMPs) and tight junctions (TJs) are implicated in METH-induced BBB damage.
  • Acetyl-L-carnitine (ALC) shows potential for BBB protection, but its mechanisms are unclear.

Purpose of the Study:

  • To investigate the neuroprotective effects of ALC against METH-induced BBB damage.
  • To elucidate the role of MMPs and Integrin-linked kinase (ILK) in METH toxicity and ALC's mechanism of action.

Main Methods:

  • Utilized the immortalized bEnd.3 cell line exposed to METH.
  • Assessed F-actin rearrangement, TJ expression (claudin-5), and MMP activity.
  • Employed ILK knockdown cells to explore ALC's role in ILK-mediated METH effects.

Main Results:

  • METH disrupted actin filaments and caused claudin-5 translocation, mediated by MMP-9 activation and ILK overexpression.
  • ALC pretreatment prevented METH-induced MMP-9 activation.
  • ALC preserved claudin-5 localization and actin filament structure.

Conclusions:

  • ALC protects BBB integrity against METH-induced damage.
  • ALC's protective mechanism involves inhibiting MMP-9 activation.
  • ILK represents a novel therapeutic target for ALC in mitigating METH toxicity.

Related Concept Videos

Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
3.1K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.6K
Phase II Reactions: Acetylation Reactions01:24

Phase II Reactions: Acetylation Reactions

Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
1.1K